M

Monte Rosa Therapeutics Inc
NASDAQ:GLUE

Watchlist Manager
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Watchlist
Price: 17.64 USD 7.04% Market Closed
Market Cap: 1.1B USD

Intrinsic Value

The intrinsic value of one GLUE stock under the Base Case scenario is 2 USD. Compared to the current market price of 17.64 USD, Monte Rosa Therapeutics Inc is Overvalued by 89%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GLUE Intrinsic Value
2 USD
Overvaluation 89%
Intrinsic Value
Price
M
Base Case Scenario

Valuation History
Monte Rosa Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about GLUE?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is GLUE valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Monte Rosa Therapeutics Inc.

Explain Valuation
Compare GLUE to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about GLUE?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Monte Rosa Therapeutics Inc

Current Assets 401.8m
Cash & Short-Term Investments 391.3m
Receivables 5m
Other Current Assets 5.6m
Non-Current Assets 58m
PP&E 52.7m
Other Non-Current Assets 5.4m
Current Liabilities 61.4m
Accounts Payable 14.5m
Accrued Liabilities 22.1m
Other Current Liabilities 24.8m
Non-Current Liabilities 152.6m
Other Non-Current Liabilities 152.6m
Efficiency

Free Cash Flow Analysis
Monte Rosa Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Monte Rosa Therapeutics Inc

Revenue
181.5m USD
Operating Expenses
-173m USD
Operating Income
8.5m USD
Other Expenses
12.4m USD
Net Income
20.9m USD
Fundamental Scores

GLUE Profitability Score
Profitability Due Diligence

Monte Rosa Therapeutics Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

37/100
Profitability
Score

Monte Rosa Therapeutics Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

GLUE Solvency Score
Solvency Due Diligence

Monte Rosa Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
57/100
Solvency
Score

Monte Rosa Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GLUE Price Targets Summary
Monte Rosa Therapeutics Inc

Wall Street analysts forecast GLUE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLUE is 21.78 USD with a low forecast of 16.16 USD and a high forecast of 28.88 USD.

Lowest
Price Target
16.16 USD
8% Downside
Average
Price Target
21.78 USD
23% Upside
Highest
Price Target
28.88 USD
64% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Monte Rosa Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for GLUE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

GLUE Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one GLUE stock?

The intrinsic value of one GLUE stock under the Base Case scenario is 2 USD.

Is GLUE stock undervalued or overvalued?

Compared to the current market price of 17.64 USD, Monte Rosa Therapeutics Inc is Overvalued by 89%.

Back to Top